Special Issue

Kinase Inhibitors in Cancer and Central Nervous System

Message from the Guest Editor

Protein kinases catalyse protein phosphorylation—a key cellular regulatory mechanism which is frequently dysregulated in human diseases. Kinases have consequently been linked to the progress of a variety of diseases, including cancer and neurodegenerative disorders. Therefore, the search for therapeutic inhibitors of specific kinases has been developed in the last three decades as a major approach to discovering new therapeutic drugs. Initially focused on the discovery, optimization, and characterization of tyrosine kinase inhibitors and on cancer indications, the field is now rapidly expanding towards serine/threonine kinases and essentially all other therapeutic indications as neurodegenerative diseases (Alzheimer's disease, Down syndrome). In this Special Issue, our goal is to highlight papers describing an intended inhibition of specific kinases, although they are not always the initial and main target of the compounds tested. In silico molecular design connected with the development of chemical syntheses and pertinent comments on the forthcoming applications of these inhibitors will be particularly appreciated.

Guest Editor

Prof. Dr. Thierry Besson

Univ Rouen Normandie, INSA Rouen Normandie, CNRS, Institut CARMeN UMR 6064, F-76000 Rouen, France

Deadline for manuscript submissions

closed (30 November 2019)



Scientia Pharmaceutica

an Open Access Journal Published by MDPI

Impact Factor 2.5 CiteScore 4.6



mdpi.com/si/19201

Scientia Pharmaceutica Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 scipharm@mdpi.com

mdpi.com/journal/ scipharm





Scientia Pharmaceutica

an Open Access Journal Published by MDPI

Impact Factor 2.5 CiteScore 4.6



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Helmut Viernstein

Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 38.1 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the first half of 2025).

